Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

被引：108
作者：
Arai, Sally [1 ]
Fanale, Michelle [2 ]
deVos, Sven [3 ]
Engert, Andreas [4 ]
Illidge, Tim [5 ]
Borchmann, Peter [4 ]
Younes, Anas [2 ]
Morschhauser, Franck
McMillan, Alex [1 ]
Horning, Sandra J. [1 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] German Hodgkin Lymphoma Study Grp, Cologne, Germany
[5] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England
来源：
LEUKEMIA & LYMPHOMA | 2013年 / 54卷 / 11期
关键词：
HIGH-DOSE THERAPY; PROGNOSTIC-FACTORS; DISEASE ANALYSIS; PHASE-II; CHEMOTHERAPY; MULTICENTER; TRIAL;
D O I：
10.3109/10428194.2013.798868
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2531 / 2533
页数：3
相关论文
共 15 条
  • [1] Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry
    Brice, P
    Bouabdallah, R
    Moreau, P
    Divine, M
    Andre, M
    Aoudjane, M
    Fleury, J
    Anglaret, B
    Baruchel, A
    Sensebe, L
    Colombat, P
    [J]. BONE MARROW TRANSPLANTATION, 1997, 20 (01) : 21 - 26
  • [2] Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
    Diehl, V
    Franklin, J
    Pfreundschuh, M
    Lathan, B
    Paulus, U
    Hasenclever, D
    Tesch, H
    Herrmann, R
    Dörken, B
    Müller-Hermelink, H
    Dühmke, E
    Loeffler, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) : 2386 - 2395
  • [3] A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
    Fehniger, Todd A.
    Larson, Sarah
    Trinkaus, Kathryn
    Siegel, Marilyn J.
    Cashen, Amanda F.
    Blum, Kristie A.
    Fenske, Timothy S.
    Hurd, David D.
    Goy, Andre
    Schneider, Stephanie E.
    Keppel, Catherine R.
    Wagner-Johnston, Nina D.
    Carson, Kenneth R.
    Bartlett, Nancy L.
    [J]. BLOOD, 2011, 118 (19) : 5119 - 5125
  • [4] High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices
    Horning, SJ
    Chao, NJ
    Negrin, RS
    Hoppe, RT
    Long, GD
    Hu, WW
    Wong, RM
    Brown, BW
    Blume, KG
    [J]. BLOOD, 1997, 89 (03) : 801 - 813
  • [5] Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma:: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)
    Josting, A
    Rudolph, C
    Mapara, M
    Glossmann, JP
    Sienawski, M
    Sieber, M
    Kirchner, HH
    Dörken, B
    Hossfeld, DK
    Kisro, J
    Metzner, B
    Berdel, WE
    Diehl, V
    Engert, A
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (01) : 116 - 123
  • [6] New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group
    Josting, A
    Franklin, J
    May, M
    Koch, P
    Beykirch, MK
    Heinz, J
    Rudolph, C
    Diehl, V
    Engert, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 221 - 230
  • [7] Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma
    Josting, Andreas
    Mueller, Horst
    Borchmann, Peter
    Baars, Joke W.
    Metzner, Bernd
    Doehner, Hartmut
    Aurer, Igor
    Smardova, Lenka
    Fischer, Thomas
    Niederwieser, Dietger
    Schaefer-Eckart, Kerstin
    Schmitz, Norbert
    Sureda, Anna
    Glossmann, Jan
    Diehl, Volker
    DeJong, Daphne
    Hansmann, Martin-Leo
    Raemaekers, John
    Engert, Andreas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) : 5074 - 5080
  • [8] A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma
    Leemhuis, T
    Wells, S
    Scheffold, C
    Edinger, M
    Negrin, RS
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (03) : 181 - 187
  • [9] Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group
    Morschhauser, Franck
    Brice, Pauline
    Ferme, Christophe
    Divine, Marine
    Salles, Gilles
    Bouabdallah, Reda
    Sebban, Catherine
    Voillat, Laurent
    Casasnovas, Olivier
    Stamatoullas, Aspasia
    Bouabdallah, Krimo
    Andre, Marc
    Jais, Jean-Philippe
    Cazals-Hatem, Dominique
    Gisselbrecht, Christian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 5980 - 5987
  • [10] A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model
    Moskowitz, CH
    Nimer, SD
    Zelenetz, AD
    Trippett, T
    Hedrick, EE
    Filippa, D
    Louie, D
    Gonzales, M
    Walits, J
    Coady-Lyons, N
    Qin, J
    Frank, R
    Bertino, JR
    Coy, A
    Noy, A
    O'Brien, JP
    Straus, D
    Portlock, CS
    Yahalom, J
    [J]. BLOOD, 2001, 97 (03) : 616 - 623
12